Why drug shortages are an ethical issue by Kerridge, I & Lipworth, W
 Australasian Medical Journal [AMJ 2013, 6, 11, 556-559] 
 
 
556 
Why drug shortages are an ethical issue 
Wendy Lipworth 1,2 and Ian Kerridge2,3  
 
1. Australian Institute of Health Innovation, University of New South Wales 
2. Centre for Values, Ethics and the Law in Medicine, University of Sydney 
3. Royal North Shore Hospital, Sydney  
 
REVIEW 
  
Please cite this paper as: Lipworth W, Kerridge I. Why drug 
shortages are an ethical issue. AMJ 2013, 6, 11, 556-559. 
http//dx.doi.org/10.4066/AMJ.2013.1869. 
 
 
 
 
 
 
Abstract 
 
Abstract 
 
Drug shortages are a growing problem in developed 
countries. To some extent they are the result of technical 
and organisational failures, but to view drug shortages 
simply as technical and economic phenomena is to miss the 
fact that they are also ethical and political issues. This 
observation is important because it highlights both the 
moral and political imperative to respond to drug shortages 
as vigorously as possible, and the need for those addressing 
shortages to do so in ethically and politically sophisticated 
ways. This brief article outlines the ethical issues that need 
to be considered by anyone attempting to understand or 
address drug shortages. 
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Introduction 
Drug shortages are an increasing problem in developed 
countries. The number of drugs that are affected by 
shortages have increased, as have the duration of 
shortages, the number of manufacturers involved in 
shortages, and the number of therapeutic classes 
affected.
1,2
 Many technical and organisational causes of 
drug shortages have been identified, relating to the ways in 
which medicines are manufactured, regulated, paid for and 
used by clinicians.
3,4
  
 
To view drug shortages simply as technical and economic 
phenomena is, however, to miss the fact that they are also 
ethical and political issues. By this we mean two things: first, 
when they arise, drug shortages threaten the capacity for 
clinicians and governments to fulfil their moral obligations 
to patients and society—specifically, to provide benefit and 
minimise harm and to promote equity. Second, drug 
shortages stem from our societal values—in particular from 
the choices we have made about what we want most from 
our pharmaceutical and biotechnology industries, our 
regulators and our health services. These observations are 
important because they highlight both the moral and 
political imperative to respond to drug shortages as 
vigorously as possible, and the need for those addressing 
shortages to do so in ethically and politically sophisticated 
ways.  
 
In this article, we describe the ethical dimensions of drug 
shortages and discuss the need for those wanting to 
prevent drug shortages to be aware of the moral trade-offs 
involved in any “solution”.  
 
How drug shortages challenge the delivery of ethical 
health care 
How drug shortages challenge the delivery of “beneficent” 
and “non-maleficent” health care  
With respect to beneficence and non-maleficence, there is 
now compelling evidence that individual patients, whole 
populations and health systems can be harmed by drug 
shortages. Individual patients can be harmed if there is no 
(equally) effective alternative therapeutic agent available to 
them as their care may be compromised, delayed or 
completely precluded. Patients can also be harmed if 
alternative agents have unexpected or unmanageable side 
effects. Further, medication errors are more likely to occur 
when clinicians and patients have to use less familiar 
medicines.
2,5-8 
 
More generally, institutions and governments may feel 
compelled to trade-off safety against access by, for 
example, allowing re-use of single-vials, allowing expired 
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drugs to be used, allowing companies to use sub-standard 
or unapproved manufacturing processes, purchasing 
compounded or imported medicines that may be of poor 
quality or even counterfeit, or expediting regulatory 
approval of new medicines.
2,3,9-12 
 
In addition to harming individual patients, drug shortages 
are a threat to public health. Indeed, others have described 
drug shortages as a “public health crisis” because they 
threaten our ability to prevent and treat both acute and 
chronic diseases.
9(p42)
 This is perhaps most obvious in the 
context of infectious diseases, where recent drug shortages 
of potentially major public health significance include 
shortages of several antimicrobial agents (increasing the risk 
of resistance and spread of diseases),
8,13,14
 shortages of 
purified protein derivative (PPD) tuberculin, which is used to 
detect tuberculosis infection;
15
 and shortages of several 
routine childhood vaccines including Haemophilus influenza 
type b (Hib), diphtheria and tetanus toxoids and acellular 
pertussis, measles, mumps and rubella, and pneumococcal 
vaccines.
16
  
 
With this in mind, it has been recognised that those making 
decisions about allocating resources need to “broaden 
(their) ethics analysis to reach beyond individually focused 
principles such as autonomy, beneficence, and non-
maleficence, to values focused on the common good, such 
as solidarity, communal beneficence and stewardship”.
9(p42)
  
 
Drug shortages also threaten the development of evidence 
and the practice of evidence-based medicine by impeding 
clinical research, with trials being made smaller, modified or 
halted altogether
17
 and by making it difficult for clinicians to 
follow evidence-based clinical practice guidelines.
18,20 
 
Finally, drug shortages harm health systems as they lead to 
governments and organisations having to commit significant 
resources to overseeing and managing the situation, and 
potentially paying more for alternative medications than 
they would normally spend.
6,10,11,21
 These expenses all have 
opportunity costs for patients and the community. 
 
How drug shortages challenge the delivery of “just” health 
care 
In many cases, drug shortages force pharmacists and 
clinicians to make difficult choices between patients in the 
allocation of scarce resources. In some cases, priority needs 
to be given to those who are youngest or most ill, whose 
diseases are progressing most rapidly, who are most likely 
to benefit from therapy and/or who are on clinical trials.
5,9,19 
Where such differentiation cannot be achieved, then 
“principled” decisions cannot easily be made to privilege 
one group over another, and other measures such as 
random allocation may be needed.
9 
 
The need for such triage, and its ethical implications, has 
been recognised by many organisations, which have 
attempted to develop guidelines for resource allocation in 
the setting of drug shortages. These guidelines have tended 
to emphasise the need for procedural integrity and justice, 
engaging all stakeholders—including clinicians, patients and 
managers—in decisions about how scarce resources should 
be allocated, and aiming for consistency, objectivity, 
transparency, accountability and clear methods for 
communicating decisions (for examples see references 9, 
17, 19, 22-24). It has also been noted that organisations 
have an ethical obligation to prepare for drug shortages by 
conserving supplies and by ensuring that the organisation is 
ready to respond to any shortage that arises.
9
  
 
Finally, drug shortages do not affect all groups of patients to 
the same extent. Certain drug classes are particularly 
vulnerable to drug shortages, including central nervous 
system agents, anti-infective agents, cardiovascular drugs, 
dermatology drugs, gastrointestinal drugs, hormones and 
synthetic substitutes, electrolytic, caloric and water balance 
agents, and cancer medicines.
1
 This means that some of the 
most disadvantaged populations, such as critically ill 
patients,
17,18
 or patients with rare metabolic diseases,
5
 are 
most likely to face the additional burden of drug shortages, 
thus increasing already existing inequities in health care 
delivery. 
 
Ethics and the aetiology and prevention of drug shortages 
The literature on the causes of drug shortages has two key 
threads. On the one hand, there is discussion of how the 
pharmaceutical industry fails to fulfil its responsibilities to 
patients, clinicians and society (“industry misconduct”). On 
the other hand, there is a focus on economic and regulatory 
processes that make drug shortages more likely (“systemic 
issues”).  
 
Industry misconduct 
With respect to the conduct of the pharmaceutical industry, 
it has been argued that the industry has been negligent by 
ceasing production of important medicines, by allowing its 
manufacturing processes to fail (or to “just pass”) regulatory 
review, by taking advantage of the fact that purchasers of 
medicines assume that they are of high quality and may not 
be able to choose their suppliers, by deliberately failing to 
inform regulators and clinicians of impending drug 
shortages and by stockpiling drugs and reselling them much 
more expensively.
2,4,10,11,25,26
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Systemic issues 
In contrast to this focus on industry misconduct, others with 
an interest in the causes of drug shortages have focused 
more on systemic issues. Shortages of generic injectable 
medicines in the United States, for example, are seen to 
stem from a combination of complex manufacturing 
processes that are vulnerable to quality control problems, 
reliance on only a few generic manufacturers with very little 
redundancy or flexibility in the manufacturing system, and 
low and competitive prices for generic drugs, placing 
pressure on producers to lower production costs, reduce 
inventories, outsource production and even stop 
manufacturing these medicines altogether—all of which 
increase the risk of drug shortages occurring.
2-4,27
 The 
relationship between regulatory processes and drug 
shortages is more contentious, and there is a debate as to 
whether regulatory actions (or lack thereof) have 
contributed to drug shortages.
3,28
 
 
While this second thread (with its focus on systemic failings) 
might seem less morally charged than the first (with its 
focus on industry misconduct), it is important to bear in 
mind that these systemic failings are themselves the result 
of what we, as a society, have decided that we want from 
our industries, our governments, and our health systems. 
We have, for example, decided to value access to affordable 
generic medicines, to allow our industries the freedom to 
decide what they do and do not manufacture and how they 
distribute these goods, and to strike a certain balance 
between aggressiveness and leniency in our regulatory 
processes.
3,27
 While these value priorities have no doubt 
promoted both commercial innovation and access to 
affordable medicines, they also contribute to drug 
shortages.  
 
Our willingness, as a society, to trust capitalism and “let 
markets work” has arguably also contributed to a number of 
perverse incentives that increase the likelihood of drug 
shortages. There are, for example, now merged companies 
that produce and market both branded products and 
generic versions of these brands. This creates an incentive 
to decrease generic production and shift demand towards 
more profitable brands.
27
 And by making generic medicines 
increasingly cheap, we are arguably driving manufacturers 
to seek lower cost production methods and production 
sites, thus increasing the risk of manufacturing problems 
and drug shortages.
3,27
 As Schweitzer argues:  
 
“If profits were low enough and the likelihood of being 
inspected and “caught” producing unsafe products were 
low enough, it could be a profit-maximising strategy to 
produce just at, or even below, the minimum acceptable 
level—and accept the consequences (as rarely as they 
occur) as another cost of doing business”.
27(p3) 
 
 
It is an open question whether these behaviours represent 
unethical conduct, or simply “rational” behaviour in a 
market system. Either way, however, our value-laden social, 
political and economic choices are obviously contributing to 
drug shortages. 
 
Conclusion 
Drug shortages are a major threat to the delivery of 
beneficent, non-maleficent and equitable health care. There 
is, therefore, a moral imperative to prevent further drug 
shortages. Indeed, it has been argued that drug shortages 
are “life-threatening public health problems” that “impose 
moral imperatives on the individuals and organisations with 
the capabilities to affect them”.
29(p144)
 
 
But drug shortages stem in part from choices that we, as a 
society, have made about how we want to organise our 
markets, our regulatory systems and our health services.  If, 
therefore, we want to prevent drug shortages, we need to 
be aware that any proposed solution will likely threaten the 
values of one or more stakeholder groups, and will demand 
moral trade-offs. As Schweitzer notes:  
 
“Solving the problem [of drug shortages] will present 
difficult choices within our health system. The choices will 
be difficult because required changes will entail reordering 
priorities”.
27(p1)
 
 
Importantly, because drug shortages are not simply a 
“pharmaceutical” or “medical” problem, but arise as a 
consequence of the way that we organise our markets and 
systems of both science and health, strategies to address 
them will likely require fundamental political and economic 
reform. As others have noted, addressing drug shortages 
will require “strong action” to promote legislative change, 
as well as local and international cooperation, transparency 
and accountability among stakeholders (including clinicians, 
policymakers, regulators, payers, patients and 
manufacturers) in both the prevention and management of 
drug shortages.
1,2,7,9,12,21,28,29
 Unless value conflicts are 
explicitly acknowledged and managed, such cooperation is 
likely to be thwarted. 
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